Hørsholm,
Chief Scientific Officer
"These are the first data on the RH5.1/Matrix-M blood-stage malaria vaccine's safety and immunogenicity in
The article can be reached via this link: https://doi.org/10.1016/S1473-3099(24)00312-8.
About University of
Since the first research license agreement in 2012, ExpreS2ion has been supporting the
Trial abbreviation | Phase | Sites | Vaccines in trial | Trial status | Year started |
VAC089 | Ia | RH5.11 R78C | Vaccinations on-going | 2023 | |
VAC086 | Ib |
MRC unit, The | RH5.2-VLP R21-VLP | Vaccinations on-going | 2023 |
VAC091 | IIb | IRSS CRUNBurkina Faso | RH5.1 RH5.2-VLP | Vaccinations on-going | 2023 |
BIO-001 | I/IIa | RH5.1 RH5.2-VLP | Screening &vaccinations on-going | 2023 | |
BIO-002 | I | RH5.1 | Vaccinations on-going | 2023 | |
BIO-003 | I | IHI BagamoyoTanzania | RH5.1 R78C | In set-up | N/A |
VAC-085 | I | Pfs48/45 | Vaccinations on-going | 2023 |
The four malaria vaccine research programs, that ExpreS2ion has a part in by virtue of basing the manufacturing on the Company's proprietary protein expression system made in Drosophila S2 insect cells, are all in the current clinical study set-up financed by grants applied for and awarded to the
1 Silk et al,
Certified Adviser
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Email: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with
https://news.cision.com/expres2ion-biotechnologies/r/publication-of-clinical-phase-ib-trial-data-for-the-adjuvanted-rh5-1-blood-stage-malaria-vaccine,c4004926
https://mb.cision.com/Main/14402/4004926/2879314.pdf
https://news.cision.com/expres2ion-biotechnologies/i/shutterstock-1262336038,c3313532
(c) 2024 Cision. All rights reserved., source